Sign in

NCT07536802RecruitingPhase 4

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial

Source: ClinicalTrials.gov · Last updated 22 Apr 2026

Brief summary (registry, in English)

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
1148 (estimated)
First submitted
10 Apr 2026
Start date
1 Jun 2025
Primary completion date
30 May 2026
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
NCT number
NCT07536802

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 1148
  • From 1 Jun 2025 to the primary completion date, 30 May 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients with heart block
  • Allergy to adenosine

Other

  • STEMI patients with cardiogenic shock at presentation
  • Patients refuse to give consent for participation

Who the study is looking for

  • All patients with acute STEMI undergoing primary PCI
  • Patients of either sex, ≥18 years of age.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Institute of Cardiovascular Diseases
Coordinator of this site? Confirm its status		KarachiPakistanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.